Purpose: To evaluate the safety of brain MR imaging examinations at 9.4 Tesla (T) as reflected in vital signs and cognitive performance in healthy and medically diagnosed adult volunteers as mandated by the regulatory agency of the Food and Drug Administration.
Introduction
Clinical magnetic resonance (MR) imaging has always been limited by sensitivity that is largely determined by the static field strength of the magnet. Human MR imaging in the 1970s operated at low magnetic fields of 0.1 and 0.3 Tesla because of the limited magnet technology and the perceived lack of penetration of RF energy into biological tissues [1, 2] . This perception was radically changed as superconducting magnets allowed the introduction of 1.5
Tesla scanner for human imaging and spectroscopy in the early 1980s [3] . This field strength became the standard for state of the art clinical scanners for the next decade. Although MR image quality improved, signal-to-noise was still limiting. Despite considerable skepticism, a prototype 3 Tesla clinical scanner was introduced in 1993 [4] , driven largely by the development of functional MRI using blood oxygenation level dependent (BOLD) contrast [5] [6] [7] [8] . The magnetic susceptibility changes of blood that form the basis of BOLD contrast increases almost quadratically with magnetic field strength [4, 9] . Not only was human fMRI dramatically improved, but clinical trials also showed greatly improved human brain anatomy that resulted in the first FDA cleared 3T scanner being introduced in 1999 [10] . Magnet manufacturing technology continued to evolve, leading to the first and only 8 Tesla scanner for human MR imaging [11] . The conservative research community pushed for 7 Tesla scanners which have received wide acceptance around the world [12] . The first 7 Tesla scanner approved by the FDA for clinical use was recently delivered [14] . Meanwhile, magnet manufacturing technology has evolved allowing higher field human sized magnets to be produced at 9.4 Tesla [15, 16] and 10.5 Tesla [17] .
Since 1982, the United States Food and Drug Administration (FDA) has maintained guidelines for human exposure to static magnetic fields [18] . After originally being set at 2T, the guideline was revised to 4T in 1997, and revised again to its current value of 8T in 2003. No subsequent revisions have been made despite higher field magnets and potential new and improved human clinical applications. Initial results [19] [20] [21] [22] [23] [24] [25] from ultra-high field systems have demonstrated emerging human applications, but safety remains an important topic for human applications at ultrahigh field. Much early speculation and theoretical analysis [26, 27] about the safety of ultra-high field imaging and some early occasional dire predictions [28, 29] , have appeared in the scientific literature. However, such sensational predictions as bulk water splitting have been shown to be unlikely to ever occur in human imaging [26] . Despite skepticism about the safety risks of long term adverse biological interactions of ultrahigh magnetic fields, the FDA and institutional review boards demand data to support this contention.
Two reports have already demonstrated the safety of human MR imaging at 9.4T in normal adults [30, 31] performed within the FDA guidelines for gradient switching and specific absorption rate (SAR). Addition investigations have been reported on the safety of MR imaging up to 8T [32] [33] [34] and of human exposure to the fringe fields of ultra-high field systems [35] . These reports have focused on healthy volunteers and reported the well-known transient sensory effects, such as vertigo or a metallic taste, but none found a safety risk. The consensus of the published ultra-high field MR safety studies is that exposure to ultra-high field MR imaging does not pose an immediate demonstratable health risk for normal adult volunteers.
Materials and Methods

Human subjects
Since this 9.4T device operates above the 8T insignificant risk guideline, an investigational device exemption (IDE) was granted by the FDA for this Institutional Review Board (IRB) approved research. Written informed consent was obtained from 22 healthy volunteers (13 male) aged 22-77 years (average 49.5 years) and 24 for-cause volunteers (8 male) aged 26-78 years (average 42.9 years). The for-cause group was made up of patients with specific clinical diagnoses including brain tumor (N=7), migraine (N=2), seizure (N=1), electrical trauma (N=4), traumatic brain injury (N=3), papilledema (N=1), dementia (N=1), aphasia (N=1), weakness (N=2), cerebrovascular disease (N=1), and depression (N=1). Individuals with a non-MR compatible implanted medical device, claustrophobia, or other contraindication to MR imaging were excluded from the study. Female subjects of childbearing potential were screened for pregnancy verbally, but also with a urine test as demanded by the Institutional Review Board. No subjects were excluded verbally or by pregnancy testing.
A short entrance interview immediately prior to imaging was given to assess the subject's anxiety and comfort.
Subjects were screened for metal objects using a metal detecting wand (Garrett Metal Detectors, Garland, TX) to minimize the risk of objects becoming projectiles in the magnetic field of the 9.4 T MR scanner.
Cognitive assessment
Cognitive testing data were collected before and after 9.4T MR imaging. Cognitive testing consisted of the Hopkins Verbal Learning Test -Revised (HVLT-R) [36] , the written (SDM-W) and oral (SDM-O) versions of the Symbol Digit Modalities (SDM) [37] , the 200 items Paced Auditory Serial Addition Test (PASAT-200), and the Letter Number Sequencing (LNS) subtest from the third edition of the Wechsler Adult Intelligence Scale [38] . These tests have been used to assess cognitive function in previous MR safety studies [30, 31] and are used routinely in clinical evaluations. All cognitive testing was performed in the earth's magnetic field in a private, quiet testing room.
Alternate versions of the HVLT-R and the SDM were used to avoid practice effects. The PASAT-200 was only administered once per subject (either before or after imaging) to avoid the large practice effect that is known for this test [39] . All other tests were given both before and after imaging. Test forms and PASAT-200 administration time (pre vs. post imaging) were randomized among subjects. Participants were not given performance feedback during the testing. Each cognitive testing session lasted between 15 and 25 minutes. 
Vital signs assessment
Vital signs were monitored before, during and after 9.4T MR imaging. These non-invasive measurements were made using an MR-compatible patient monitoring system (Precess, InVivo Corp, Jacksonville Fl). Heart rate, respiratory rate, blood pressure, end-tidal carbon dioxide (ETCO 2 ), and peripheral arterial oxygen saturation percentage (O 2 -sat) were measured three times at approximately one minute intervals with the subject lying supine with a leg support under their knees, with their head in the radiofrequency (RF) coil, and blankets covering them for warmth. The triplicate measurements were taken with the subject's head positioned outside the magnet at 2.6 m from isocenter in a magnetic field of approximately 0.3T and again while at isocenter in a magnetic field of 9.4T.
Subjects were moved into and out of the magnet bore at a constant rate of less than 4 cm/sec. This maximum rate has been found to minimize the discomfort of moving though the fringe field gradient to isocenter of the static magnetic field of the 9.4T magnet. The vital sign measurements were repeated after imaging while the subject's head was at 9.4T and again after being removed from the magnet back to 0.3T.
Subjective assessment of the MRI experience
Subjects completed a short verbal exit interview to assess their experience of participating in this research protocol.
The interview included questions about discomforts commonly experienced during exposure to strong static magnet fields (e.g., vertigo or metallic taste) as well as questions about participant anxiety and comfort. Participants were encouraged to give complete details (e.g., intensity, frequency, and duration, time and location sensation experienced) about any sensations experienced.
Data Analysis
Cognitive assessment
For-cause and healthy subjects were analyzed separately for all cognitive test analyses. The cognitive performance tests were scored and the raw performance data were analyzed for each test. The PASAT-200 performance data were analyzed with a one-way ANOVA to test for a statistically significant change in performance due to 9.4T MR imaging (before vs. after imaging) at a 95% confidence level. Data from each remaining cognitive test were analyzed with a one-way ANOVA with repeated measures for a statistically significant change in performance due to 9.4T MR imaging (before vs. after imaging) at a 95% confidence level. A small number of subjects did not complete some of the post-imaging, cognitive testing due to fatigue or by time constraints imposed by the subjects.
Test data from these subjects were removed from the analysis.
Vital signs assessment
The for-cause and healthy subjects were analyzed separately. The vital sign data were analyzed for statistically significant changes due to exposure to either the 9.4T static magnetic field or non-proton MR imaging. A two-way analysis of variance (ANOVA) with repeated measures was performed on the measured data for each vital sign type to test for changes attributable to magnet field strength (0.3T vs. 9.4T) and 9.4T MR imaging (before vs. after imaging) at a 95% confidence level. There were not enough for-cause subjects to analyze each disease type separately. Data were censored from analysis when recognizable technical problems prevented accurate data collection. The most common cause for censoring was the nasal cannula not remaining in position, leading to unreliable ETCO 2 and respiratory data. Since the subjects were provided noise isolating earphones, the nasal cannula had to be taped in place rather than being secured around the ears as is normally done. This leaves the cannula more susceptible to being dislodged when the subject is moved into and out of the magnet.
Imaging protocol
All data were collected using a custom-built 9.4T MR scanner (80 cm diameter warm bore) optimized for human brain imaging [15] . Non-proton MR imaging was performed using a custom-built sodium ( 23 Na) birdcage RF coil tuned to 105.92 MHz. A maximum of 60 minutes of sodium imaging was permitted by the Institutional Review Board on each subject. Imaging had to remain within the current FDA guidelines for gradient switching and SAR.
Only the 9.4T static magnetic field was outside the FDA insignificant risk guidelines. The maximum gradient amplitude and slew rate used for imaging were 5.47 mT/m and 150 mT/m/ms, respectively. The global SAR was monitored in real-time and the total value (watt-seconds) accumulated for all acquisitions was recorded. Individual acquisitions were completed in less than 10 minutes using a flexible twisted projection imaging (flexTPI) acquisition [40] . Subjects wore earplugs and noise isolating headphones during imaging.
Results
All 46 subjects completed the protocol without incident. One for-cause subject withdrew prior to imaging due to discomfort from the "spinning feeling" experienced while being moved into the magnet. On average, subjects underwent 46.7 ± 10.2 minutes of imaging and accumulated 13,223 ± 4,420 watt-seconds of energy exposure.
Tables 1 and 2 summarize the p-values from the analyses of cognitive test performance and vital sign data, respectively. Table 3 shows the number and details of subjects reporting various sensations. The most commonly reported sensation was sleepiness (healthy=9, for-cause=8) and nervousness (healthy=4, for-cause=6).
Discussion
After accounting for multiple comparisons, none of the cognitive performance or vital sign data were statistically significant at a 95% confidence level. This matches the findings of previous safety investigations [30, 31] , but extends this finding to for-cause subjects for the first time at 9.4T. Although not unexpected, regulatory agencies have demanded experimental data in both normal and for-cause subjects in the evaluation of safety at this higher field. Individually, only one cognitive test and four different vital sign measurements were found to be significant (p-value < 0.05).
Only the oral version of the Symbol Digit Modalities cognitive test (SDM-O) given before and after imaging was found to have a significant change (p< 0.05) and only for the for-cause subjects ( Table 1) showed no significant changes in performance from exposure to 9.4T imaging in normals or for-cause subjects.
The vital sign data (Table 2 ) and the review of the original vital sign data over time (not shown) revealed no clinically significant safety concerns and any statistically significant changes were not clinically significant. The O 2 saturation of healthy subjects decreased less than 1% between outside the magnet (0.3T) and at magnet isocenter (9.4T) locations. This small change was not observed in the for-cause subjects or in previous studies and is within the error of this measurement for the equipment used. The average O 2 saturation throughout the study remained above 95%. The systolic blood pressure of for-cause subjects was lower after imaging (119.6 ± 17.3 mmHg) compared to before imaging (121.9 ± 18.0 mmHg). Similarly, it was also lower on average when the subjects were at magnet isocenter (119.21 ± 16.87 mmHg) than when they were 2.6 m from isocenter in a field of 0.3T (122.28 ± 18.31 mmHg). Both of these changes are likely due to the subjects lying supine and becoming more relaxed as the study progressed; several subjects reported sleeping during imaging. Inspection of the systolic blood pressure over time for the forcause subjects revealed that the highest average blood pressure was measured at the beginning of the study, before entering the magnet with the subject's head in a field of 0.3T. This measurement is most susceptible to bias from anxiety of participating in the study, an effect that has been previously observed [30] . Table 3 : Reported sensations reported during entrance and exit interviews. a One subject reported feeling lightheaded when sitting up after imaging. Other subjects reported vertigo or a "spinning sensation" when being moved into or out of the 9.4T scanner; A Subjects reported vertigo or a "spinning sensation" when being moved into or out of the 9.4T scanner; b Subjects reported being cold during imaging or while in the scanner; B Three subjects reported being cold during scanning. One subject reported feeling a slight increase in temperature during one acquisition but not all acquisitions. One subject reported feeling cold during most acquisition and slightly warmer during one acquisition; c Three subjects reported feeling nervous about the imaging or during the imaging. One subject reported anxiety due to the proximity of the RF coil; C Five subjects reported feeling nervous about the imaging. One subject reported nervousness due to "feeling cramped" during the study;
Condition
d Subject reported experiencing a metallic taste when being moved into the scanner; D Subject reported that they always have a metallic taste but experienced a slight increase in the sensation when being moved into the scanner; e One subject reported having "restless leg syndrome" and also feeling a tingling in the mouth near a dental implant.
One subject reported tingling and twitching in the toes throughout scanning. One subject reported tingling in the hand before any imaging. Three subjects reported non-continuous twitching/tingling during no more than two acquisitions; E Three of the subjects reported muscle twitching or tingling during the entrance interview and that they
